Triple negative breast cancer cells (TNBC) presently have no targeting therapies as TNBC cells lack the over expression of HER2, PR and ER, so therapy is limited to chemotherapy and the prognosis for TNBC patient treatments is often poor. This evidence concerns the gene PGR and breast cancer.